Piper Sandler Maintains Overweight on Ocular Therapeutix, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Biren Amin maintains an Overweight rating on Ocular Therapeutix (NASDAQ:OCUL) with a $15 price target.
June 21, 2024 | 5:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler's analyst Biren Amin has reaffirmed an Overweight rating on Ocular Therapeutix, maintaining a price target of $15.
The reaffirmation of an Overweight rating and a $15 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100